• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

i-Fect Scores Again
This study is the first to demonstrate that the stabilization of HIF1A expression underpins the development of bortezomib-induced neuropathic pain. Crucially, these findings reveal that the initiation and maintenance of bortezomib-induced neuropathic pain are regulated by distinct mechanisms.
Source: Neuromics - May 13, 2019 Category: Neuroscience Tags: chemotherapy i-Fect RNAi siRNA siRNA delivery in-vivo Source Type: news

i-Fect in Action
This study is the first to demonstrate that the stabilization of HIF1A expression underpins the development of bortezomib-induced neuropathic pain. Crucially, these findings reveal that the initiation and maintenance of bortezomib-induced neuropathic pain are regulated by distinct mechanisms.Looking to up your odds for high percentage siRNA Transfection? Try i-Fect.
Source: siRNA and DsiRNA Transfection Efficiency - May 9, 2019 Category: Neuroscience Tags: Chemotherapy i-Fect in vivo RNAi neuropathic pain siRNA delivery in-vivo Source Type: news

The association of neuronal stress with activating transcription factor 3 in dorsal root ganglion of in vivo and in vitro models of bortezomib-induced neuropathy.
This study exhibited important mechanistic insight into how BTZ induces neurotoxicity through the activation of ATF3 resulting in intracellular oxidative stress, mitochondrial dysfunction, cell apoptosis, and ER stress and provided a novel potential therapeutic target by blocking ATF3 signaling. PMID: 30289077 [PubMed - as supplied by publisher]
Source: Current Cancer Drug Targets - October 3, 2018 Category: Cancer & Oncology Authors: Yin Y, Qi X, Qiao Y, Liu H, Yan Z, Li H, Liu Z Tags: Curr Cancer Drug Targets Source Type: research

Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy
Publication date: Available online 10 November 2015 Source:Brain, Behavior, and Immunity Author(s): Cuicui Liu, Shuo Luan, Handong OuYang, Zhenzhen Huang, Shaoling Wu, Chao Ma, Jiayou Wei, Wenjun Xin Bortezomib (BTZ) is a frequently used chemotherapeutic drug for the treatment of refractory multiple myeloma and hematological neoplasms. The mechanism by which the administration of BTZ leads to painful peripheral neuropathy remains unclear. In present study, we found that application of BTZ at 0.4 mg/kg for consecutive 5 days significantly increased the expression of CCL2 in DRG, and intrathecal administration of n...
Source: Brain, Behavior, and Immunity - November 13, 2015 Category: Neurology Source Type: research

Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy.
Abstract Bortezomib (BTZ) is a frequently used chemotherapeutic drug for the treatment of refractory multiple myeloma and hematological neoplasms. The mechanism by which the administration of BTZ leads to painful peripheral neuropathy remains unclear. In present study, we found that application of BTZ at 0.4 mg/kg for consecutive 5 days significantly increased the expression of CCL2 in DRG, and intrathecal administration of neutralizing antibody against CCL2 inhibited the mechanical allodynia induced by BTZ. We also found an increased expression of c-Jun in DRG, and that inhibition of c-Jun signaling prevented the...
Source: Brain, Behavior, and Immunity - November 7, 2015 Category: Neurology Authors: Liu C, Luan S, OuYang H, Huang Z, Wu S, Ma C, Wei J, Xin W Tags: Brain Behav Immun Source Type: research

Synergistic anti‐myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide
Abstract The proteasome inhibitor bortezomib is an effective therapy for the treatment of relapsed and refractory multiple myeloma (RRMM); however, prolonged treatment can be associated with toxicity, peripheral neuropathy and drug resistance. Our earlier studies showed that the novel proteasome inhibitor marizomib is distinct from bortezomib in its chemical structure, mechanisms of action and effects on proteasomal activities, and that it can overcome bortezomib resistance. Pomalidomide, like lenalidomide, has potent immunomodulatory activity and has been approved by the US Food and Drug Administration for the treatment o...
Source: British Journal of Haematology - October 12, 2015 Category: Hematology Authors: Deepika S. Das, Arghya Ray, Yan Song, Paul Richardson, Mohit Trikha, Dharminder Chauhan, Kenneth C. Anderson Tags: Research Paper Source Type: research